September will see the 30th anniversary of one of the most groundbreaking legislative acts affecting the US pharmaceutical industry – the Drug Price Competition and Patent Term Restoration Act of 1984, more commonly known as the Hatch-Waxman Act after its chief sponsors. In honor of this landmark industry development, the Thomson Reuter’s Generics Practice Area […]
written on 17.03.2014